Ivonescimab Shows High Pathological Complete Response Rate in Phase II Lung Cancer Study

A Phase II trial of ivonescimab in perioperative resectable non-small cell lung cancer (NSCLC) achieved a 50.7% pathological complete response (pCR) rate, a significantly higher figure compared to existing standard-of-care treatments. Published in Nature Medicine, these findings suggest ivonescimab could be a promising new therapy, particularly for squamous histology and PD-L1-negative patients who historically have poorer outcomes.